Understanding how a specific receptor affects T cells during organ rejection
Official title: Role of the CD43 Receptor on Effector CD8+ T Cells During Acute Allograft Rejection
Funded at Johns Hopkins University · NIH-11125031 · Data updated 2026-11-12
This study is looking at how a specific receptor on immune cells called CD8+ T cells affects kidney transplant patients, especially during times when the body might reject the new organ, to find better ways to prevent rejection and help transplants last longer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | August 8, 2024 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $327,500 |
| NIH project number | 1R56AI179856-01A1 |
| Project ID | NIH-11125031 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have received a kidney transplant and are at risk of acute rejection.
✕Less likely to help
Patients who have not undergone organ transplantation or those with stable grafts without rejection episodes may not benefit from this research.
What this research studies
This research investigates the role of the CD43 receptor on CD8+ T cells, which are crucial in the body's immune response during acute organ rejection. By examining how these T cells respond to transplanted organs, the study aims to uncover mechanisms that lead to graft failure. The researchers will analyze the activation and behavior of CD43+ T cells in kidney transplant patients, focusing on their role in acute rejection episodes. This could lead to improved strategies for preventing organ rejection and enhancing long-term transplant success.
Why it matters
Potential benefit: If successful, this research could lead to better treatments that prevent acute rejection of transplanted organs, improving long-term survival rates for transplant patients.
How similar studies have gone: Previous research has shown promising results in understanding T cell responses in transplantation, but the specific role of CD43 in this context is still being explored.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Krummey, Scott M — Johns Hopkins University
- Study coordinator: Krummey, Scott M
Related research
Other NIH-funded projects on the same topics.
-
Injecting immune-boosting medicine into melanoma tumors to help the immune system reject them
This gives an immune-boosting drug directly into melanoma tumors in pet dogs to help their T cells find and destroy the cancer.
-
Immunological mechanisms behind treatment-resistant kidney transplant rejection
This grant explores why certain kidney transplant rejections don’t respond to standard treatments and what immune cells in the graft are driving that resistance.
-
Targeting graft T cells to reduce transplant rejection
A patient-facing study exploring how immune cells within transplanted organs drive rejection and how we might reduce trouble for people who need organ transplants.
-
Engineered kidney 'chip' to study antibody-driven rejection and how the body adapts
A kidney-rejection research grant is developing a miniaturized, human cell–based chip to model how antibodies cause rejection and how kidneys may adapt.
-
Social media, mood, and teens: how the menstrual cycle affects rejection feelings and online experiences
Teenagers using social media may feel stronger negative reactions to online feedback, especially around certain times in their menstrual cycle, which could relate to mood and depression.
-
Understanding how BK virus links infection to kidney transplant rejection
This project looks at how BK polyomavirus reactivation affects kidney transplant patients and aims to use pre-transplant T cell information to tailor immunosuppression and monitoring.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.